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T en-Y ear  R esu lts  of  a R a n d o m iz e d  T r ia l  E v a lu a t in g  
P ro lon ged  L o w -D o se  A d ju v a n t  C h e m o t h e r a p y  in  
N o d e-P o s i t iv e  B rea s t  C ancer:  A J o in t  E u r o p e a n  
O rgan iza t ion  for  R e s e a r c h  and T r e a t m e n t  of  
C a n c e r - D u t c h  B rea s t  C an cer  W o r k in g  P a r ty  S tu d y
By Pieter C. Clahsen, Cornelis J.H. van de Velde, Kees Welvaarf-, Ocker J. Repelaer van Driel, Richard J, Sylvester,
and Cooperating Investigators
Purpose: To investigate whether treatment with pro­
longed low-dose adjuvant chemotherapy could improve 
survival of patients with axillary node-positive breast 
cancer.
Patients and Methods: Four hundred fifty-two pa- 
tients with axillary node-positive breast cancer who re­
ceived postoperative irradiation were prospectively ran­
domized in a trial (European Organization for Research 
and Treatment of Cancer [EORTC] 09771) that compared 
surgery followed by prolonged low-dose chemotherapy 
versus surgery alone. Chemotherapy was given for a 
period of 2 years and consisted of monthly courses of 
cyclophosphamide 50 mg/m2 orally on days 1 to 14, 
methotrexate 15 mg/m2 intravenously on days 1 and 8, 
and fluorouracil 350 mg/m2 intravenously on days 1 and 
8 (CMF).
Results: At a median follow-up time of 10 years, the 
overall survival duration was significantly prolonged in 
the chemotherapy arm (hazards ratio, 0.75; 95% confi­
dence interval, 0.56 to 0.99; P = .04). Ten-year overall 
survival rates (± SE) were 59% (± 3.6%) for the chemo­
therapy arm and 50% (± 3.7%) for the control arm. Time 
to local relapse was significantly prolonged in the che­
motherapy arm (hazards ratio, 0.63; 95% confidence in­
terval, 0.42 to 0.94; P = .02). Patients with one to three 
positive axillary nodes and patients with estrogen recep­
tor-negative tumors especially benefited from chemo­
therapy. Toxicity w as observed in 93% of patients.
Conclusion: We conclude that prolonged low-dose 
adjuvant CMF can significantly prolong overall survival 
in patients with node-positive breast cancer. However, 
considering the fact that toxicity w as still considerable 
despite reducing the dose of chemotherapy by 50%, we 
believe that conventionally dosed short-term regimens 
are preferable in the treatment of node-positive breast 
cancer.
J Clin Oncol 73:33-47.
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HE FIRST RANDOMIZED clinical trial on systemic comparing CMF versus no therapy in 1973, this rapidly
therapy in breast cancer was initiated by Fisher et 
al1 in 1958 and studied the issue of whether short-couvse 
adjuvant thiotepa could improve survival in early breast 
cancer. The rationale for this design was to determine
became one of the most widely studied regimens in the 
treatment of breast cancer. Results from several random­
ized clinical trials indicated that advantages were most 
pronounced in women less than 50 years of age.10 To
whether tumor cells spread during the surgical procedure determine the optimal duration of chemotherapy became 
could be killed by chemotherapy administration during then the second-generation goal for investigators, and 
the first 72 hours after surgery. In 1968, Nissen-Meyer data from several investigators showed that regimens us- 
et al2 used a similar design in a trial of patients with 
breast cancer who received a 6-day course of cyclophos­
phamide. Greenspan3 was among the first to introduce 
successfully combination therapy in breast cancer in the 
early 1960s. After the discovery of the active regimen of 
vincristine, prednisone, cyclophosphamide, methotrexate 
and fluorouracil (CMFVP) in the treatment of metastatic 
disease by Cooper et al4 in 1968, subsequent trials focused 
on the study of various combinations of these chemother­
apeutic agents. The acceptance of the concept that in a 
large group of patients, foci of metastatic cells were al­
ready present at the time of diagnosis led to the conclusion 
that repetitive courses of drugs were required to destruct 
these tumor cells.5'7 Furthermore, a review by DeVita 
et al8 in 1975 showed that the results of combination 
chemotherapy were superior to those of single-agent ther­
apy. When finally Bonadonna et al9 initiated their study
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ing 4 to 6 months of therapy were likely to be as effective 
and were probably preferable to 12 months of ther­
apy.“ As a result, a recommendation was finally made at 
the Consensus Development Conference in 1986 that 6- 
month courses of CMF should become the standard treat­
ment for women with axillary node-positive breast cancer 
younger than 50 years of age.12
However, at the time, when the first preliminary but 
promising results of adjuvant CMF in axillary node-posi­
tive breast cancer were published by Bonadonna et al9 in 
1976, many controversies were also raised about the ef­
fects of the regimen on overall survival and the concern 
whether short-term or long-term side effects could even­
tually be detrimental.
Therefore, a prospectively randomized trial was de­
signed in the Netherlands (European Organization for Re­
search and Treatment of Cancer [EORTC] 09771) to be 
performed under the auspices of the Breast Cancer Coop­
erative Group of the EORTC, comparing treatment with 
low-dose CMF administered over 2 years versus surgery 
alone. This design aimed to reduce toxicity while main­
taining the same total dose of chemotherapy as was ad­
ministered in the regimen used by Bonadonna et al.9 The 
trial was started in 1976 and closed to patient entry in 
1980. It included premenopausal and postmenopausal ax­
illary node-positive patients with early breast cancer who 
underwent either a radical mastectomy or modified radical 
mastectomy before being randomized.
In the present 10-year follow-up report, we show that 
both overall survival and toxicity data were comparable 
with those of the conventional 12-month CMF regimen 
used by Bonadonna et al,9 despite the fact that dosages 
were reduced by 50% and therapy was given over a period 
of 2 years.
PATIENTS AND METHODS
Trial Design
Women with axillary node-positive breast cancer from 20 different 
hospitals in the Netherlands were randomized in a multicenter phase 
III trial (EORTC 09771) comparing surgery followed by a prolonged 
regimen of low-dose adjuvant chemotherapy versus surgery alone.
Central randomization and registration were performed after sur­
gery and histopathologic confirmation of positive axillary nodes by 
means of a telephone call to the EORTC Data Center in Brussels, 
Belgium. Randomization was based on random permuted blocks and 
was stratified for institution, menopausal status, and nodal status 
(one to three positive nodes or ^  four positive nodes).
Patient Population
Trial entry criteria included informed consent given by the patient 
according to the institute’s regulations, preoperative ly staged and 
histologically confirmed diagnosis of Tla,2a,3aN0,IM0 breast can­
cer, surgery with curative intent, (modified) radical mastectomy, and 
one or more histopathologically confirmed positive axillary nodes.
Patients were ineligible if they were older than 70 years of age, 
had bilateral breast cancer, had a well documented history of another 
neoplasm (except basal cell carcinoma), had distant metastases, had 
metastases in the infraclavicular lymph nodes, had received previous 
treatment for breast cancer in addition to (modified) radical mastec­
tomy, had a WBC count ^  4.0 X 10y/L, had a platelet count <  130 
X 10‘YL, had a serum creatinine level more than 105 ¿¿moI/L, had 
an alkaline phosphatase level that had repeatedly been above the 
normal value, were conditionally or mentally unfit, or were pregnant 
or lactating at time of diagnosis.
Treatment
Surgery consisted of either radical or modified radical mastectomy 
(according to Madden13) that included a total axillary dissection in 
which the infraclavicular top nodes were separately marked.
Postoperative radiation therapy had to start within 6 weeks after 
surgery. In patients with one to three positive axillary nodes, internal 
mammary-chain irradiation with 40 Gy was administered over 4 
weeks. In cases of four or more positive axillary nodes, supraclavicu­
lar and axillary nodes were irradiated using 50 Gy over 5 weeks, in 
addition to the parasternal irradiation.
After surgery, all patients were randomized either to receive 2 
years of adjuvant chemotherapy or to be monitored by observation. 
Chemotherapy was given for a period of 2 years and consisted of 
monthly courses of cyclophosphamide 50 mg/m2 orally on days 1 
to 14, methotrexate 15 mg/m2 intravenously on days I and 8, and 
fluorouracil 350 mg/m2 intravenously on days 1 and 8. Between the 
completion of radiation therapy and the start of chemotherapy, pa­
tients were observed for a period of 7 to 10 days, which could be 
prolonged if the WBC count was less than 4.0 X 109/L. The dose 
reduction in case of World Health Organization (WHO) grade 1 
hematologic toxicity was 50% for cyclophosphamide and methotrex­
ate, whereas the dose of fluorouracil was not reduced in case of 
grade 1 toxicity. In case of WHO grade 2 hematologic toxicity, 
cycles of CMF were discontinued until grade 1 toxicity was reached. 
In case of serious gastrointestinal toxicity leading to mucosal lesions 
of the mouth and throat and/or watery diarrhea, fluorouracil and 
methotrexate were temporarily withdrawn. Cyclophosphamide treat­
ment was interrupted when hemorrhagic cystitis occurred. In case 
of a serum creatinine level greater than 105 /¿mol/L, treatment with 
methotrexate was temporarily stopped. No additional hormonal treat­
ment was given to any of the patients randomized.
Follow -  Up Examinations
Follow-up examinations were requested every 3 months during 
the first 5 years after surgery. Minimal requirements were physical 
examination, performance scale assessment, and two serum liver 
tests. For trial purposes, a chest x-ray and a bone scan were per­
formed every 6 months and a mammography was performed once 
per year. After 5 years, progress reports were sent once per year 
and contained information about the disease and survival status of 
the patients. All data were reviewed centrally by the study coordina­
tors, a research fellow, and the data manager.
Criteria o f  Evaluation
Disease-free survival was defined as the time between the date of 
randomization and the date of disease progression or death, which­
ever came first.
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Table 1. Characteristics of Eligible Patients According to Treatment
Characteristic Total
Adjuvant
Chemotherapy Control
No. of patients 437 224 213
Menopausal status (%)
Premenopausal 216 50.4 48.4
Postmenopausal 221 49.6 51.6
Surgical procedure (%)*
Radical mastectomy 132 34.6 27.8
Modified radical mastectomy 284 63.6 71.2
Other 6 1.8 1.0
No. of invaded nodes (%]
1-3 325 74.1 74.6
> 4 112 25.9 25.4
Estrogen receptor status (%)
Negative 77 16.5 18.8
Borderline 25 7.1 4.2
Positive 147 33.0 34.3
Unknown 188 43.3 42.7
Tumor size (%)t
^ 2 cm 105 26,9 23.0
> 2 cm 315 73.1 77.0
* For 1 5 patients, information on surgical procedure was not available, 
t  For 17 patients, information on krrnor size was not available.
Statistical Methods
Overall and disease-free survival curves were estimated using the 
Kaplan-Meier product-limit method14 and compared using the log- 
rank test.15 Estimates of hazards ratios, their 95% confidence inter­
vals, and two-sided P  values were calculated using both an unad­
justed Cox proportional hazards regression model and a model 
stratified according to the number of positive axillary nodes (one to 
three or >  four) and including covariates for menopausal status, 
surgical procedure, estrogen receptor status, and clinical tumor size 
(if sufficient data were available for these covariates).16
RESULTS
From October 1976 to November 1980, 452 patients 
were randomized by 20 hospitals from the Netherlands. 
Of these 452 patients, 14 were ineligible for the study 
because they had an inadequate disease staging (n = 3), 
distant metastases (n = 7), previous treatment (n = 1), a 
second malignancy (n = 2), or were older than 70 years 
of age (n = 1), One patient could not be included in 
the statistical analyses because no follow-up data were 
available after randomization. The data of the remaining 
437 patients (97%) were used in the analyses of this 
study. The cut-off date for this report was July 1993, 
when the median follow-up time was 10 years (maximum, 
17 years).
The characteristics of eligible patients were well dis­
tributed among the two treatment arms (Table 1). The 
mean number of axillary nodes removed per patient was 
11.9. Although not requested in the protocol, data on
tumor estrogen receptor content could retrospectively be 
retrieved for 249 patients.
Table 2 lists the percentages of patients who were af­
fected by toxicity on at least one occasion. Only 6%  of 
patients had grade 3 (WHO) WBC counts and no grade
4 toxicity was observed- Likewise, for platelet counts, no 
grade 3 or 4 toxicity could be detected. In the majority 
of the patients, nausea and vomiting developed during 
the administration of chemotherapy. One third of patients 
had alopecia, while other side effects, such as infection, 
stomatitis, and cystitis, were relatively rare. Seven percent 
of patients had no toxicity recorded at all. No toxic deaths 
occurred among patients treated with prolonged Iow-dose 
chemotherapy.
Reliable data on the date of starting and ending chemo­
therapy, doses actually given, and toxicity could be col­
lected for 142 of 224 patients in the chemotherapy arm. 
Of these, 114 (80.3%) received at least six cycles of 
chemotherapy, 103 (72.5%) received at least 12 cycles 
of chemotherapy, and 65 (45.8%) received 24 cycles of 
chemotherapy. The mean interval between surgery and 
initiation of chemotherapy was 62 days. The mean rela­
tive dose-intensities actually given and initially targeted 
were 0.33 and 0.45, respectively (calculated according to 
the method described by Hryniuk et al17 and relative to the 
entire 36 weeks of the Cooper regimen4). No significant 
relationship between mean relative dose-intensity actually 
given or targeted and clinical outcome could be detected. 
When examining the duration of therapy, patients who 
had received 23 or more courses of chemotherapy had a 
significantly better overall survival than patients who had 
received less than 23 courses (P = .001), However, it 
should be noted that patients who received less courses 
of chemotherapy may have relapsed earlier and therefore 
had a worse survival.
Of 437 patients, 242 relapsed and 194 died. Time to
Table 2. Toxicity Among Patients Who Received Chemotherapy
Toxicity No. of Patients %
Hematologic'*
WBC 9 6.4
Platelets 0 0.0
Side effects
Nausea 122 88.4
Vomiting 82 59.4
Infection 9 6.5
Stomatitis 27 19.6
Cystitis 7 5.1
Alopecia 49 35.3
Other 35 26.1
No toxicity 10 7.0
* WHO grade 3 or 4.
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Fig 1. Time to local relapse 
among 437 patients with axil­
lary node-positive breastcancer.
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local relapse was significantly prolonged in the chemo­
therapy arm (hazards ratio, 0.63; 95% confidence interval, 
0.42 to 0.94; P = .02) (Fig 1). However, this effect could 
not be demonstrated for time to distant metastases (haz-
ards ratio, 0.89; 95% confidence interval, 0.68 to 1.18; P 
-  .43) (Fig 2). There was a trend for treatment effect in 
favor of chemotherapy for disease-free survival (hazards 
ratio, 0*84; 95% confidence interval, 0.66 to 1.07; P —
Fig 2» Time to distant metas­
tases among 437 patients with 
axillary node-positive breast
cancer.
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Fig 3, Disease-free survival 
among 4 3 7  patients with axil­
lary node-positive breast cancer.
(years)
Number of patients at risk ;
224 180 144 107 84 CM F
213 149 116 86 67 Control
.15) (Fig 3). Ten-year disease-free survival rates (± SE) interval, 0.56 to 0.99; P — .04) (Fig 4). This advantage
were 43% (±  3.5%) for the chemotherapy arm and 36% 
(± 3.6%) for the control arm.
for the chemotherapy arm was due to a reduction in cancer 
deaths and no difference was found between the number 
Overall survival time was significantly prolonged in the of noncancer deaths in the two randomized treatment
chemotherapy arm (hazards ratio, 0.75; 95% confidence arms (data not shown). Ten-year overall survival rates (
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Table 3. Overall Survival Among 437 Patients With Node-Positive Breast Cancer, According to Treatment, Menopausal Status, Surgical Procedure,
Number of Invaded Nodes, Estrogen Receptor Status, and Tumor Size
Variable No. of Patients No, of Events 10-Year Survival (%) Hazards Ratio 95% Cl P
All patients
Adjuvant chemotherapy 224 92 59 0.75 0.56-0.99 .04
Control 213 102 50
Menopausal status
Premenopausal
Adjuvant chemotherapy 113 42 64 0.75 0.49-1.14 .17
Control 103 45 54
1 -3 positive nodes
Adjuvant chemotherapy 85 28 68 0.65 0.39-1.08 .09
Control 79 33 55
^ 4 positive nodes
Adjuvant chemotherapy 28 14 51 0.99 0.45-2.18 ,98
Control 24 12 49
Postmenopausal
Adjuvant chemotherapy 111 50 53 0.76 0.52-1.11 .15
Control 110 57 46
1 -3 positive nodes
Adjuvant chemotherapy 81 32 59 0.78 0.49-1.25 .30
Control 80 37 53
sz 4 positive nodes
Adjuvant chemotherapy 30 18 41 0.69 0.36-1.31 ,26
Control 30 20 30i
Surgical procedure
Radical mastectomy
Adjuvant chemotherapy 75 42 49 0.81 0.51-1.28 ,36
Control 57 34 42
Modified radical mastectomy
Adjuvant chemotherapy 138 47 63 0,67 0.46-0.98 .04
Control 146 63 54
Axillary nodal status
1*3
Adjuvant chemotherapy 166 60 64 0.71 0.50-1.00 .05
Control 159 70 54
^ 4
Adjuvant chemotherapy 58 32 44 0.83 0.51 -1.36 .45
Control 54 32 39
Estrogen receptor status
Negative
Adjuvant chemotherapy 37 16 56 0.58 0.30-1.U .10
Control 40 23 35
Borderline
Adjuvant chemotherapy 16 9 55 0.74 0.25-2.20 .59
Control 9 6 44
Positive
Adjuvant chemotherapy 74 33 48 1.05 0.64-1.70 .85
Control 73 32 58
Unknown
Adjuvant chemotherapy 97 34 66 0.67 0.42-1.06 .08
Control 91 41 51
Tumor size (cm)
-  9
Adjuvant chemotherapy 58 23 63 0.71 0.39-1.30 .26
Control 47 20 51
> 2
Adjuvant chemotherapy 158 68 56 0.78 0.56-1.08 .13
Control 157 78 50
NOTE. Hazards ratios, 95% confidence intervals, and P values were calculated using an unadjusted Cox proportional hazards model. 
Abbreviation: Cl, confidence interval.
SE) were 59% (± 3.6%) for the chemotherapy ami and 
50% (± 3.7%) for the control arm. Table 3 list the hazards 
ratio and 10-year overall survival rates by treatment group 
according to different patient characteristics. The treat­
ment effect appeared to be proportionally the same for 
premenopausal and postmenopausal patients, although 
differences between the che ino therapy group and the con­
trol group were no longer statistically significant. Patients 
with one to three positive axillary nodes benefited from 
chemotherapy, whereas this advantage was not observed 
for patients with four or more positive nodes. The magni­
tude of the treatment effect seemed to be the largest 
among the subgroups of premenopausal patients with one 
to three positive axillary nodes and patients with estrogen
LOW-DOSE ADJUVANT CHEMOTHERAPY IN NODE-POSITIVE BREAST CANCER 39
receptor-negative tumors. A significant advantage in fa- tomy especially benefited from chemotherapy, whereas 
vor of chemotherapy was observed for the group of pa- patients who underwent a radical mastectomy did not, a 
tients who had undergone modified radical mastectomy statistically significant difference that still existed after
(hazards ratio, 0.67; 95% confidence interval, 0.46 to adjusting for tumor size. Although this difference in treat-
0.98; P = .04). In patients who had undergone radical ment effect was probably due to the smaller number of
mastectomy, no advantage for chemotherapy could be 
observed. The effect of chemotherapy appeared to be the 
same for patients with tumors s  2 cm and those with
events in the radical mastectomy group, a similar observa­
tion was made in the first report of the Milan trial I, in 
which advantages for CMF were more pronounced in 
tumors greater than 2 cm. All of these results were con- patients who underwent less extensive surgery.9
firmed by a multivariate analysis stratified for the number Our study showed a significant decrease in local re-
of positive axillary nodes and adjusted for the covariates lapses after 10 years, although a similar effect could not
menopausal status, surgical procedure, estrogen receptor 
status, and tumor size (data not shown). However, it 
should be noted that differences within these subsets 
could be due to chance. Moreover, statistical power is
be demonstrated for distant métastasés. In the majority 
of poly chemotherapy studies in the past, investigators 
usually did not provide a breakdown for relapse-free sur­
vival by time to local relapse and time to distant metasta- 
lost when multiple analyses are performed on smaller ses. Overgaard et al2() conducted a study comparing che-
subgroups. motherapy with or without radiotherapy in high-risk
For 69 of 113 premenopausal patients randomized to breast cancer patients (T3-4 and/or node-positive). Re- 
the chemotherapy arm, reliable data were available con- porting an extremely high number of locoregional recur- 
cerning whether drug-induced cessation of menses had rences, probably due to an inadequate method of axillary
occurred. In this particular subgroup, no significant differ­
ence could be observed in overall or disease-free survival
dissection (only a mean of 6.3 lymph nodes was re­
moved), the investigators concluded that systemic therapy
between patients with menses (n = 50) and those without after nonradical mastectomy did not prevent locoregional 
menses (n = 19) (data not shown). recurrences. Another interesting observation was made in
the trial conducted by Fisher et al,21 who compared total 
mastectomy versus segmental mastectomy versus seg- 
Our study showed that treatment with low-dose CMF mental mastectomy plus radiation therapy in a study in
DISCUSSION
continued for 2 years could significantly improve survival 
in patients with node-positive breast cancer. A search in 
the literature showed that our study was the only random-
which all node-positive patients received chemotherapy, 
Although no information about time to local recurrence 
was given, distant metastases-free survival was not sig-
ized trial until now to compare a low-dose CMF regimen nificantly different when total mastectomy versus seg-
mental mastectomy and total mastectomy versus segmen­
tal mastectomy plus radiation therapy were compared. 
However, overall survival was borderline significantly 
different in favor of segmental mastectomy and segmental 
mastectomy plus radiation therapy, respectively.
Our observations indicated that there was a 40% reduc­
tion in the odds of local recurrence in the CMF arm, 
taking into consideration that all patients in both treatment 
arms had already received postoperative irradiation. This 
effect of chemotherapy on local relapse is still present 
and statistically significant at 10 years of follow-up. The 
proportionally small and nonsignificant effect oil distant 
results suggest that survival advantages for the chemo- métastasés in our study suggests that local control did
with no further treatment in patients with node-positive 
breast cancer. Another low-dose adjuvant chemotherapy 
study that compared CMF with cyclophosphamide alone 
was performed in Denmark, but failed to demonstrate any 
difference in outcome between the two treatment arms (n 
= 805) at 6 years.18
Interestingly, we found a significant difference in over­
all survival in favor of chemotherapy, but this could not 
be shown for disease-free survival. We only observed a 
reduction in cancer deaths and, therefore, this finding was 
not due to differences in noncancer deaths. Although we 
are aware of the limitations of subgroup analyses, our
therapy treatment arm were most pronounced for pre­
menopausal patients with one to three positive axillary 
nodes. Moreover, no advantage for chemotherapy was 
observed for patients with four positive nodes. These 
observations are in line with the conclusions from the 
overview of randomized clinical trials in early breast can­
cer.19 Patients who underwent a modified radical mas tec-
have an impact on overall survival. On the other hand, 
the advantage for overall survival may also have been 
caused by an early prevention of distant métastasés by 
chemotherapy. Future studies on chemotherapy and radio­
therapy should address more precisely the question of 
whether therapy has an effect on local recurrence and 
distant métastasés, which may help to study further the
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relationship of these end points with overall survival. In no detrimental effect of a longer duration of chemother-
addition, they should try to focus on the fact whether apy on the number of courses that could be administered.
the sequence of chemotherapy and radiotherapy has any However, despite the fact that chemotherapy doses were
importance for the prevention of locoregional recurrences reduced by 50%, toxic side effects were still observed in
and distant metastases. 93% of patients, compared with a 96% toxicity rate re-
When the first results of the Milan trial I that studied ported in the Milan trial I. Although the method of re-
12-month cycles of CMF were published in 1976, an porting toxicity may have been different, this observation
advantage in favor of chemotherapy could only be ob- was probably partly related to the fact that in our trial
served for disease-free survival, although toxicity was design, treatment had to be continued for 2 years to obtain
the same total dose of chemotherapy. Consequently, pa­
tients also had twice the chance to experience any toxic-
considerable.9 However, 10-year results confirmed the ef­
fect on disease-free survival and showed a trend for over­
all survival in all patients (P = .10),22 Both disease-free ity, which might have hidden the possible beneficial effect
survival and overall survival benefits were significant in of reducing the dosage of chemotherapy by 50%. 
premenopausal women, and results were inversely related The conclusion that must be drawn from this study is
to the number of positive axillary nodes. Taking into that prolonged low-dose adjuvant CMF can significantly
consideration that our patient population contained a improve overall survival in patients with node-positive
slightly larger proportion of premenopausal patients and breast cancer. The lack of a standard-dose chemotherapy
patients with one to three positive axillary nodes, overall arm in this study limits the conclusions that can be made
regarding the efficacy to standard-dose therapy. However, 
taking into consideration the long treatment duration and
survival percentages in this trial are still highly compara­
ble to those reported in the Milan trial I.22 This result is 
particularly significant in view of the fact that our dose- its considerable toxicity, it is likely that a cost-benefit 
intensities calculated according to the method reported comparison would show an advantage for short-term 
by Hryniuk et al17 were much lower than those obtained CMF regimens. Several randomized trials have already
in the Milan trial 1.
One o f the objectives of the present trial was to study
shown that shorter courses of polychemotherapy are as 
effective in prolonging survival as prolonged courses.19
whether adjuvant treatment with a low-dose CMF regi- Moreover, results of the Cancer and Leukemia Group B
men could also improve survival, but with less toxicity. 
Therefore, chemotherapy doses used in the present trial 
were approximately 50% of those used in Milan trial I.9 
Although it has been shown by Tancini et al23 in 1983
8541 trial have recently demonstrated that women who 
were treated with a high or moderate dose-intensity had 
a significantly better survival than those treated with a 
low dose-intensity.24 In view of these data, we believe
cancer.
that 6 months of CMF were equally effective as 12 that conventionally dosed short-term chemotherapy regi -
months, the total dose of chemotherapy administered was mens are preferable to prolonged low-dose regimens in
considered to be important at the time this trial was de- the treatment of patients with axillary node-positive breast 
signed. Therefore, treatment with low-dose CMF was
continued for 2 years, The percentage of patients who
completed all 24 cycles was 45.8%, which is comparable
to the 44.9% who received the complete treatment of 12
cycles in the Milan trial l!} This suggests that there was
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